Tags Posts tagged with "cannabis stock news"

cannabis stock news

0 691
Marjuana-Stocks-cannabis biotech

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

Bernard Fortier is a graduate from the MBA program at l’école des Hautes Études Commerciales (HEC) in Montreal, with over 20 years of international experience in management and business development in the biopharma, specialized medical nutrition and medical fields.

Mr. Fortier spent 5 years in the USA working in the therapy and rehabilitation market, having graduated from the physiotherapy program at Laval University. His experience in the USA enabled him to work on business development and management early in his career. After completing his MBA in 2001, he joined the pharmaceutical industry with a biotechnology company. He spent 8 years in various key commercial roles at Serono Canada (now EMD Serono) in the Multiple Sclerosis field, including National Sales Manager for the Neurology business unit.

In 2010, Bernard became the Country Manager for Nutricia Canada, the specialized medical nutrition division of Groupe Danone. He was recruited in 2012 to launch a new pharmaceutical company called Orimed Pharma. Through licensing deals and internal product development, the company’s portfolio grew from 3 to 10 products within 4 years.

“I am very pleased to welcome Bernard to the team as our new CEO as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, Chairman of Tetra Bio-Pharma. “Bernard is an experienced leader and executive with proven skills in leadership, strategy and execution, as well as business development and negotiation. Mr. Fortier has a clear mandate from the Board, to grow revenue and build Tetra as a global leader in pharmaceutical cannabis. Going forward, we will be placing considerable efforts in expanding Tetra in the U.S. market.”

Corporate Update:

Mr. Andre Rancourt, previous interim CEO was elected to the position as Chairman of the Board of Directors. The Board has mandated Mr. Rancourt to continue taking an active and dynamic role as he demonstrated as Interim CEO. Mr. Rancourt will be responsible for the administration, overall corporate governance and financing of the corporation.

Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a member of the Board. The Corporation wishes to thank Mr. Audet for all his efforts in working to grow Tetra where it is today and looks forward to his continued participation in building Tetra as a global leader in pharmaceutical cannabis.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(TBP.CN)(CNSX:TBP)(TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

0 714

The marijuana industry is often thought to be male dominated until Cali Premium Produce CEO Priscilla Vilchis came on the scene. Vilchis is one of Los Angeles County’s final 13 marijuana applicants.

As the city prepares for its new cannabis industry, local government Lynwood City Council gave preliminary approval for 13 different applicants to secure a position in LA County’s new industry. The approval was given at a board meeting on July 18th.

Among the applicants is one of Los Angeles County’s first legal growers is Cali Premium Produce, Inc. CEO Priscilla Vilchis. Out of Lynwood’s over 100 applications, Vilchis was recommended to receive two licenses for cultivation and production.

A Woman On A Mission To Become A MMJ Industry Powerhouse

Vilchis is the only minority woman on the list of the 13 pre-approved applicants, helping to bridge the barrier between multi-million dollar companies, and people trying to enter the industry. Vilchis has helped to turn many companies into successful businesses growing their revenues into the millions before even entering the medicinal cannabis market.

The new adult use licenses will help Vilchis’s company to accomplish their goal of cultivating and harvesting the highest-quality cannabis flower available for wholesale to the California market. They also have the goal of maintaining responsible use, education, public safety and job creation.

In Las Vegas, in 2014, the Los Angeles based entrepreneur opened her first cannabis venture when her company Premium Produce, LLC was awarded two licenses from the Nevada Department of Health and Human Services.

Vilchis has been called the ‘Queen of the Desert’ which has ensured her place among the American Cannabis pioneers. Her hometown of Lynwood is a small town in Los Angeles County and among one of the first cities within the country to give out permits since the marijuana legalization laws passed on November 8th.

with many possibilities for a new market in marijuana, many are excited to see where Vilchis will take the industry.

0 298

MassRoots Announces Closing of $1.2 Million Equity Financing

Capital will be used to Grow Point-of-Sale and Regulatory Compliance Market Share in Emerging Cannabis Markets, with a Focus on California

MassRoots, Inc. (MSRT), one of the leading technology and compliance platforms for the cannabis industry, is pleased to announce it has closed a $1,217,000 private placement of common stock and warrants, as detailed in MassRoots’ Current Report on Form 8-K filed on July 24, 2017 with the U.S. Securities and Exchange Commission. MassRoots’ Chairman and only over 5% shareholder, Mr. Isaac Dietrich, participated in the offering along with several “accredited investors,” including family offices and high net worth individuals.

In July 2017, MassRoots acquired Odava, a leading point-of-sale and regulatory compliance platform for cannabis dispensaries. Odava’s main integration to state regulators is through Franwell, Inc.’s METRC system, which was recently awarded the contract for California’s cannabis regulatory reporting system. MassRoots expects this will enable Odava to enter the California market with minimal infrastructure changes. With more than 1,000 dispensaries expected to be subject to California state regulations for the first time, this presents a unique growth opportunity for MassRoots to on-board these dispensaries to the Odava system as well as its other product offerings.

California is the largest regulated cannabis market in the country and while our platform is available in other states, our main priority is aggressively scaling our market share in the Golden State,” stated MassRoots’ Chief Executive Officer Mr. Isaac Dietrich. “The proceeds from this offering will help us take advantage of the opportunity created by our recent acquisition of Odava and the California regulatory contract being awarded to Franwell.”

For more information, please see MassRoots’ recent Corporate Overview Deck, Shareholder Update, and filings with the U.S. Securities and Exchange Commission.

About MassRoots
MassRoots, Inc. is one of the leading technology platforms for the regulated cannabis industry. Powered by more than one million registered users, the Company’s mobile apps empower consumers to make educated cannabis purchasing decisions through community-driven reviews. Its compliance and point-of-sale system, Odava, enables cannabis-related businesses to streamline their retail operations and compliance reporting to state regulators. With a significant market share of medical cannabis patients in certain markets, more than 25,000 shareholders, equity financings and warrant exercises of more than $17 million since inception, the Company believes it is uniquely positioned to best serve the needs of the cannabis industry. For more information, please visit MassRoots.com/Investors and MassRoots, Inc.’s filings with the U.S. Securities and Exchange Commission.

Forward-looking Statements
Certain matters discussed in this announcement contain statements, estimates and projections about the growth of MassRoots, Inc.’s business, partnerships, new features, acquisitions, user growth and related business strategy. Such statements, estimates and projections may constitute forward-looking statements within the meaning of the federal securities laws. Factors or events that could cause our actual results to differ may emerge from time to time. MassRoots undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The recipient of this information is cautioned not to place undue reliance on forward-looking statements. For more information, please refer to MassRoots, Inc.’s filings with the U.S. Securities and Exchange Commission.

0 1795

A Tempe, Arizona based company named Harvest of Arizona with retail shops throughout Tempe and Scottsdale, has announced a merger this past Tuesday that would in turn make it one of the largest companies in the growing industry.

The deal will in theory be a benefit to the state’s already registered 115,000 patients by lowering prices and bringing with it more variety than ever.

A Marijuana Industry PowerHouse

The merger is occurring with another Arizona cultivator named Modern Flower, currently the leading wholesale supplier in the state. The company has stated that it will soon become “the largest medical marijuana operator in Arizona.”

By January of this year, Harvest will own eight dispensaries and in addition, seven cultivation centers within the state of Arizona, said the company’s CEO, attorney Steve White.

White also was quoted saying that the merger will improve competition, not stifle it. An interesting thought as the company monopolizes on the industry.

With Harvest becoming the state’s largest wholesaler, it will be able to influence the prices of its various vendors while bringing down retail prices.

As more competition enters the market inevitably, prices are expected to come down.

The Arizona Department of Health Services, which grants licenses and oversees the state’s medical marijuana program, reports that 98 dispensaries currently open in the state. Last October, the state decided to give out more licenses than ever, granting 130 licenses to various entrepreneurs looking to open new shops and cannabis-growing facilities across the state. This is expected to increase tax revenues and open the market more than ever.

White has predicted that by 2018, the Arizona industry may be producing more marijuana flowers than can be consumed by patients, which simple economics states would cause prices to fall.

Harvest is expected to triple the number of its employees from around 100 to 300 by next year giving new possibilities, and leaving expansion on the rise.

2 1509

In the past year, the marijuana industry has been a monster in terms of growth. Many investors have decided to jump right in to this new industry with profits hitting all time highs. It is not out of the ordinary to see some marijuana stocks that have doubled or even tripled in value over the past 12 months.

With an industry that is expected to grow from around $5 billion to a whopping $17 billion by 2021, why not jump right in? Those numbers put the industry at a 300% legal sales growth with opportunities unexplored including new states legalizing the drug, organic growth within legal states, and the opportunity to move the black market into legal channels. The opportunity for marijuana is incredible. Here’s four stocks that have grown a substantial 10% in the last week.

1.Cara Therapeutics (+12.8%)
A market favorite for its large, quick, gains, Cara Therapeutics (NASDAQ: CARA) had unfortunately lost more than half of its market value in a two-week timeframe. Last week, Cara unexpectedly found its place and grew almost 13%.

One major piece of news seems to be the cause here. On July 12th Cara announced it data for its phase 1 trial of oral CR845, a treatment for pain and pruritus (itching) in patients with chronic kidney disease who are undergoing hemodialysis. All of the data was very promising.

2. Aphria (13.2%)
One of the Canadian giants in the industry, Aphria (NASDAQOTH: APHQF) had an exceptional week, growing over 13%. Many speculate that this is due to its fourth-quarter and full-year results for the fiscal year of 2017. The company did report a loss however in its fourth-quarter report but the $5.5 million is all accounted for in the companies new plans for expansion and growth. The largest strong spot of their report was a 25% decrease in all-in cash costs from 2016 to $1.31 a gram. As demand rises and costs fall, the company is expected to continue this growth trend.

3. Aurora Cannabis (+16.1%)
The largest gainer of the week among marijuana stocks with a 16% gain, was Aurora Cannabis (NASDAQOTH: ACBFF), yet another Canadian medical-cannabis producer. Aurora happens to be one of Aphria’s largest competitors. Aurora recently announced that it is in the process of developing what they call ‘the Aurora Sky project’. The project is essentially an 800,000 square foot facility that the company claims will be the most advanced and automated in the world. It is scheduled to be completed early next year.

One of the main reasons why Aurora skyrocket is an announcement that it would move from the TSX Venture Exchange to the much larger Toronto Stock Exchange. This move comes from a significant boost in the companies market cap over the past year, and could be just the jump investors need to get their feet wet.

1 2326

Aside from the smokeable product we all know and love, the hemp plant has many promising opportunities in its future which are bringing in lots of new investors into the market.

Many mistake help for cannabis, and though it comes from the same plant it is undoubtedly a different product. Marijuana is grown to have THC (the main psychoactive component) at extremely high levels, while hemp only has trace amounts of around less than 0.3% of the hallucinogen. Because of its low THC content, you could smoke a pound of it and never feel any high. However, the seeds are still considered a Schedule I narcotic.

The plant is traditionally used in various ways such as textiles, ropes and more. This is due to its strength as a fabric. After around a month of growth, the hemp stalk is so sturdy that it is almost impossible to break. For culinary use, the seeds are pressed to produce an oil that can be processed into a flour from which products like pasta, bread, and many other possibilities can be created.

Hemp has a large appeal to be used as a food due to its potential in the market. Hemp is known as a superfood in the same category as flax and chia seeds, with long-term, sustainable play in the market. Products using hemp flour are not only some of the highest in protein, but they contain 20 amino acids, including nine that the body cannot product. In addition, it has extreme health benefits such as, immune boosting, weight suppressant, and an ability to lower blood pressure and cholesterol. It is also a big hit with vegetarians because it is high in the fatty acids omega-3 which is found in food like salmon.

For all these reasons and more, hemp seems to be on the rise with no show in sight of slowing down. With large potential on the market to fill the healthy food section, the possibilities hemp holds are endless.

0 4693
Marijuana-Stocks-Money Nug

Recreational marijuana has been an especially hot topic in the United States after Nevada became the fifth state to have a legal program on July 1st.

Companies levered to the Nevada marijuana market have benefited greatly from this and we want to highlight 2 companies levered to this opportunity.

• mCig (MCIG) issued a shareholder update last week and reported that its Grow Contractors division will shatter its previous record revenue numbers after it took on cultivation management contracts and delivered on its plan for cultivation and production ownership. Grow Contractors has a proven track record of success in Nevada and the boom in the state has led to an influx of requests for work. We are favorable on the company’s diverse operating structure, attractive debt-free balance sheet, its improving fundamentals, and its growth prospects, especially in Nevada and California.

• Terra Tech (TRTC) is one of the best-known marijuana stocks and the company has benefited the combination of its leverage to the Nevada market and its investor awareness. While we are favorable on the company’s brand recognition, we are cautious with the shares due to Terra Tech’s financial structure which is dilutive in nature. The company has tried to raise capital through private placements but has not been successful. Terra Tech has only been able to raise capital by issuing and selling stock and this is not a shareholder friendly way to raise money. We would become more favorable on the firm if it sold off one of its subsidiaries (Edible Gardens) to support its cannabis related capital needs.



Pursuant to an agreement between MAPH and mCig Inc. (MCIG), we were hired for a period beginning 7/1/2017 – 12/1/2017 to publicly disseminate information about (MCIG), including on the Website and other media including Facebook and Twitter. We are being paid 3 million common restricted shares of mCig, Inc. by mCig, Inc.  We may buy or sell additional shares of (MCIG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 2029

Cannabis is often thought to be a cause backed by only the most liberal, left-wing participants. Recently, dozens of high-profile conservatives have outwardly supported the decriminalization as well as the legalization of cannabis.

The principles behind legalization are generally labelled as conservative issues. The issues of states’ rights, limited government, and personal sovereignty come into play with all cannabis legislation as it is a fight between state and federal government.

One prolific figure in the cannabis fight is none other than David Koch. Koch has advocated for the decriminalization of cannabis since the early 1980s. This is not highly publicized since it seemingly contradicts conservatives usual points, but it is indeed factual.

Koch was once quoted stating, “I have friends who smoke pot… It’s ridiculous to treat them as criminals.”

While many do not agree with David Koch on everything, his thoughts on cannabis seem to be spot on. Koch is not the only high-profile conservative recently associated with the decriminalization and legalization movement.

The founder of Christian Broadcasting Network & Christian Coalition, Pat Robinson was quoted saying, “I really believe we should treat marijuana the way we treat beverage alcohol. I’ve never used marijuana and I don’t intend to, but it’s just one of those things that i think: this was on drugs just hasn’t succeeded.”

Here are a few more quotes from several high profile conservatives in case you didn’t see it already.

“[I]t is our judgment that the war on drugs has failed, that it is diverting intelligent energy away from how to deal with the problem of addiction, that it is wasting our resources, and that it is encouraging civil, judicial, and penal procedures associated with police states. We all agree on movement toward legalization, even though we may differ on just how far.” National Review, Editorial Board
“Yes [marijuana should be legalized federally]. Public opinion has changed… The distinction between marijuana and alcoholic beverages is really not much of a distinction… The prohibition against selling and dispensing alcoholic beverages has I think been generally, there’s a general consensus that it was not worth the cost. And I think really in time that will be the general consensus with respect to this particular drug [marijuana].” John Paul Stevens, Former U.S. Supreme Court Justice
“[If] you want to go somewhere where you can smoke medicinal weed, then you ought to be able to do that.” Rick Perry, Secretary of Energy
“I think it’s about time we legalize marijuana… We either put people who are smoking marijuana behind bars or we legalize it, but this little game we are playing in the middle is not helping us, it is not helping Mexico and it is causing massive violence on our southern border… Fifty percent of the money going to these cartels is coming just from marijuana coming across our border.” Glenn Beck
“I find the way people trivialize this issue to be infuriating. I hold it to be self-evident that people should be allowed to grow plants in their own gardens, regardless of what kind of plants they are… I do think the prohibition on this is outrageous… What we’re living through is a farce.” Andrew Sullivan, Conservative Blogger & Author
What the authorities should do is decriminalize pot use. You wanna do it in your house, not bother anyone? Fine.” Bill O’Reilly
“Someone has got to break the logjam. The fact is that you have the incarceration rate, particularly in African American communities for drug related crimes is off the charts… The old mindset that doesn’t address the current environment, that doesn’t deal with realities of our penal system or our sentencing system… A lot of folks are getting caught in the cross-hairs… We’ve got to reorient our priorities here when it comes to the issue of drugs in our culture.” Michael Steele, Former Chairman of Republican National Committee.
We need to prioritize our law enforcement efforts, and if somebody’s gonna smoke a joint in their house and not do anybody else any harm, then perhaps there are other things that our cops should be looking at to engage in and try to clean up some of the other problems that we have in society that are appropriate for law enforcement to do.” Sarah Palin, Former Governor of Alaska & Republican Vice-Presidential Nominee
Ask the Facebook generation whether we should put a kid in jail for the nonviolent crime of drug use and you’ll hear a resounding ‘no.’” Rand Paul, U.S. Senator
So, if liberals and conservatives see the same on this issue, how long will it take to move forward for decriminalization and legalization?

0 1338

In 2016, sales of marijuana and marijuana related products surged to almost $7 billion. If that seems like a lot, it’s only just beginning. At this point, almost 30 states have some sort of legalization or decriminalization which shouldn’t be surprising regardless of your views. The continuation of this process is inevitable. As states see not only the progress but the profit from taxes that states such as California are making, all states will push for legalization of the green plant.

In 2014, marijuana sales in the U.S. topped out at around $2.7 billion, with half of that coming from California’s medical marijuana industry. Today, California alone is expected to hit $5 billion in its medical marijuana market once regulations are all ironed out. For scale, the Los Angeles market is alone worth more than $1 billion dollars (the same revenue as Colorado pulled in last year).

By the year 2024, marijuana sales are projected to reach almost $21 billion dollars and some estimations suggesting a much higher number for the whole of the marijuana industry in the U.S. of $50 billion by 2026.

From all these numbers, it is clear that we are still in the very early stages of legalization. The volume of startups involved in the industry is reaching an all time high with most of the companies springing up in the last 5 years.

The market for marijuana does not just include selling weed in a sketchy storefront. The market includes pharmaceuticals made by some of the largest pharma companies in the world, a range of companies devoted solely to edible forms of the plant, satellite companies dedicated to the transportation of money for dispensaries, security companies and every other possibility. The options are endless, and the market will continue to grow as long as there is a place for it.

With the continuation of legalization and decriminalization across the country, the push for this industry is now inevitable.

0 444

National Research Council and Lexaria Bioscience Commence Laboratory Work

As earlier reported, several studies will be initiated in the coming months designed to optimize Lexaria’s patented technology enabling delivery of lipophilic active agents within foods, beverages, capsules and other ingestible formats. These studies will investigate lipophilic active agent classes including cannabinoids, vitamins, NSAIDs, and nicotine.

Advanced analytical techniques including mass spectrometry and nuclear magnetic resonance testing will be used to evaluate the chemical nature of the molecular association that Lexaria’s technology is believed to form between lipophilic active agents and the flavor and delivery enabling fatty acid agents that are integral to Lexaria’s formulation methodologies. Practical applications of this work could include further broadening or strengthening of Lexaria’s intellectual property portfolio and may also provide the foundation for new commercial arrangements.

“We are delighted to have commenced formulation development and characterization work together with the NRC,” stated John Docherty, president of Lexaria Bioscience. “The NRC team has extensive knowledge and experience in the field of lipid based delivery systems relating to pharmaceutical products, natural health products and functional foods. This collaboration will significantly assist Lexaria in further developing and characterizing its IP portfolio.”

Additional information will be released upon completion and interpretation of test results.

About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

For regular updates, connect with Lexaria on Facebook (https://www.facebook.com/Lexaria-Corp-106280556370600/) and Twitter (https://twitter.com/lexariacorp)


This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods, Ambarii, and ViPova™ products are not intended to diagnose, treat, cure or prevent any disease.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements